SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of
PD-1
immunotherapy
metastatic cancer
spartalizumab
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
06 Oct 2022
06 Oct 2022
Historique:
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
7
10
2022
Statut:
aheadofprint
Résumé
Improved selection of cancer patients who are most likely to respond to immune checkpoint inhibitors remains an unmet clinical need. Recently, a positive correlation between levels of
Identifiants
pubmed: 36200668
doi: 10.2217/fon-2022-0660
doi:
Banques de données
ClinicalTrials.gov
['NCT04802876']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Novartis